ABOUT US
Management
김건수 (Gunsoo Kim)
He began his career as a researcher in charge of novel project discovery at Hanhwa Solution Central R&D center. Afterwards, he spent 10+ years at LG chem to serve as a researcher developing a novel drug for the treatment of diabetes, an inspector to revise GMP regulations and operating system, a member of the project discovery team reviewing and and introducing external R&D projects and also, a member of the R&D strategy planning team to select R&D projects, budget management and etc. At CHA Biotech, he was in charge of R&D strategy establishment and External Cooperation.
His experience in various stages of pharmaceutical industry easily enlightened him to realize the potential of CAR-T cell therapy. Ever since the establishment, he has successfully led Curocell to make history in CAR-T therapy industry and become the most advanced CAR-T specialized company in Korea.
김형철 (Hyung Cheol Kim, Ph.D.)
박진경 (Jin kyong Park)
서현진 (Hyeonjin Seo)
조수희 (Su-Hee Cho, M.D.)
전동혁 (Dong Hyuk Jeon)
김정근 (Jungkun Kim)
Mr. Kim has a bachelor’s degree in mechanical engineering from Jeonbuk National University, Korea. He had successfully led projects of biotech manufacturing facilities from design for the process, utilities, and facilities for procurement and construction management. He also has experience in assuring clean room environment and perform commissioning and qualification for facility equipment.
Currently, he is responsible for project management, GMP utility management, facility inspection, and EHS at Curocell.
박영삼 (YoungSam Park)
Through more than 16 years of experience in the biopharmaceutical industry including analyzing small molecules, proteins, and cell therapy. He has established the analytical methodology required during the process of CAR-T therapy development. He also has experience in developing in-vitro assays, mass spectrometer analysis, and most recently, cell analysis utilizing cutting-edge technologies including ddPCR and flow cytometry.
이영호 (Young-ho Lee, Ph.D.)
Board of Directors
공동창업자 / 이화여자대학교 부교수
공동창업자 / 서울대학교 교수
History
2023
11
코스닥 기술성장특례 상장
04
신규 사옥(연구소, 본사) 및 상업용 GMP 완공(과학벨트 둔곡신동 거점지구)
02
2종 면역관문수용체 발현억제 기술관련 특허 미국 등록
01
연세대학교의료원 백혈병 임상계약 체결
2022
11
서울성모병원 백혈병 임상계약 체결
05
부산대학교병원 림프종 임상계약 체결
05
국립암센터 림프종 임상계약 체결
05
㈜입셀과 CAR-NK 공동연구 계약 체결
01
서울아산병원 림프종 임상계약 체결
01
St. Jude Hospital과 렌티바이러스 기술도입 계약 체결
2021
12
서울대학교병원 림프종 임상계약 체결
12
2종 면역관문수용체 발현억제 기술 관련 특허 유럽 등록
12
「2021년 벤처창업진흥유공 포상」창업활성화 분야 대통령 표창
11
2종 면역관문수용체 발현억제 기술관련 특허 국내 등록
09
과학기술부, 산업통상자원부, 보건복지부 국가신약개발사업 선정
02
국내 최초 CAR-T 치료제 식약처 IND 승인
01
삼성서울병원 림프종 임상계약 체결
2020
04
보건복지부 첨단의료기술개발사업 선정
03
임상용의약품 제조를 위한 GMP 완공(삼성서울병원 미래의학관 위치)
2019
05
과학기술부 기술이전사업화사업(투자연계형 R&BD) 선정
01
CAR-T 치료제 개발 공동 추진을 위한 삼성서울병원과 MOU 체결
01
2종 면역관문수용체 발현억제 기술관련 특허 국내 및 PCT 출원
2018
04
중소벤처기업부 지역특화산업육성사업 선정
04
보건복지부 첨단의료복합단지 기반 기술구축사업 선정
2017
06
중소벤처기업부 민간투자주도형 기술창업지원사업 선정(TIPS)
06
기업부설연구소 인증
2016
12
㈜큐로셀 법인 설립